Home > > > Report Detail

Spinal Muscular Atrophy Market, Global Forecast by Countries, Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) & Companies

Publisher Name :
Date: 14-Nov-2018
No. of pages: 121
Inquire Before Buying

Spinal muscular atrophy is a disease that causes muscle weakness which mostly appears in newborn children. Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally.  Spinal muscular atrophy is basically 4 types – Type 1, Type 2, Type 3 and Type 4. Most patients suffers with Spinal muscular atrophy type 1. According to Renub Research Global Spinal Muscular Atrophy (SMA) market is anticipated to grow at a CAGR of 14.29 percent in future. This double digit growth rate will happen due to expected launch of new drugs, better reimbursement options and decline in drugs prices.

Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of new born children in which patients are not in position to sit in their lifetime and normally they die within 6 months.  In spinal muscular atrophy type 2, patients can sit but cannot walk.  Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during the adulthood.

This report titled “Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)” studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years

At present only Biogen’s Spinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc.  Other companies are also working for new drugs development and they hope to enter in the market place very soon as their drugs are in Phase III clinical trials.  

By Country - Market Segmentation

Spinal muscular atrophy market by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is a leading market place due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure.

By Total & Treated Patients - Population Segmentation

Spinal muscular atrophy Total & Treated Patients by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is dominating in the treated SMA patients globally.

By Drugs - Market Segmentation

The report by Renub Research studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales.

The Report has been analyzed from 9 Major Viewpoints


  • Global Spinal Muscular Atrophy Market (Present & Forecast)

  • Global Spinal Muscular Atrophy Market Share, Patients Share, Treated Patients Share (Present & Forecast)

  • Country Spinal Muscular Atrophy Market (Present & Forecast)

  • Country Spinal Muscular Atrophy Patients Population (Present & Forecast)

  • Country Spinal Muscular Atrophy Treated Patients Population (Present & Forecast)

  • Spinal Muscular Atrophy Drugs Sales (Present & Forecast)

  • Global – Clinical Study on Spinal Muscular Atrophy & Drugs Pipeline

  • Growth Drivers and Challenges

  • Key Spinal Muscular Atrophy Companies Initiatives and Financial Insight


Country Covered in this Report


  • United States

  • United Kingdom

  • France

  • Germany

  • Italy

  • Spain

  • Japan


Drugs Details Covered in this Report


  • Spinraza

  • AVXS-101

  • CK2127107

  • RG7916

  • Olesoxime

  • LMI070


Company Covered in this Report


  • Biogen Inc.

  • Roche AG

  • Novartis AG

  • Cytokinetics Inc

Spinal Muscular Atrophy Market, Global Forecast by Countries, Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) & Companies

Table of Contents

1. Introduction
1.1 Market Definition
1.2 Currency Conversion

2. Research Methodology

3. Executive Summary

4. Global Spinal Muscular Atrophy Market and Patients Analysis
4.1 Spinal Muscular Atrophy Market
4.2 Spinal Muscular Atrophy Patient Numbers
4.3 Spinal Muscular Atrophy Treated Patient Number

5. Share Analysis – Global Spinal Muscular Atrophy
5.1 Country Market Share
5.2 Patients Population Share
5.3 Treated Patients Share

6. United States
6.1 Spinal Muscular Atrophy Market
6.2 Spinal Muscular Atrophy Patient Numbers
6.3 Spinal Muscular Atrophy Treated Patients

7. United Kingdom
7.1 Spinal Muscular Atrophy Market
7.2 Spinal Muscular Atrophy Patient Numbers
7.3 Spinal Muscular Atrophy Treated Patient Numbers

8. Germany
8.1 Spinal Muscular Atrophy Market
8.2 Spinal Muscular Atrophy Patient Numbers
8.3 Spinal Muscular Atrophy Treated Patients

9. Italy – Spinal Muscular Atrophy
9.1 Spinal Muscular Atrophy Market
9.2 Spinal Muscular Atrophy Patient Numbers
9.3 Spinal Muscular Atrophy Treated Patient Numbers

10. France – Spinal Muscular Atrophy
10.1 Spinal Muscular Atrophy Market
10.2 Spinal Muscular Atrophy Patient Numbers
10.3 Spinal Muscular Atrophy Treated Patient Numbers

11. Spain
11.1 Spinal Muscular Atrophy Market
11.2 Spinal Muscular Atrophy Patient Numbers
11.3 Spinal Muscular Atrophy Treated Patient Numbers

12. Japan
12.1 Spinal Muscular Atrophy Market
12.2 Spinal Muscular Atrophy Patients
12.3 Spinal Muscular Atrophy Treated Patient Numbers

13. Drugs Sales – Spinal Muscular Atrophy
13.1 Spinraza
13.2 AVXS-101
13.3 CK2127107
13.4 RG7916
13.5 Olesoxime
13.6 LMI070

14. Spinal Muscular Atrophy Study Status Analysis
14.1 Spinal Muscular Atrophy Clinical Study
14.2 Spinal Muscular Atrophy Drugs Development Pipeline

15. Growth Drivers
15.1 Increasing Funding for Research & Development
15.2 Biogen Access Programs

16. Challenges
16.1 High Treatment Cost
16.2 Common Side Effects

17. Biogen Inc.
17.1 Business Overview
17.2 Initiatives/Strategies
17.2.1 Point 1
17.2.2 Point 2
17.2.3 Point 3
17.3 Financial Insight

18. Novartis AG
18.1 Business Overview
18.2 Initiatives/Strategies
18.2.1 Point 1
18.2.2 Point 2
18.3 Financial Insight

19. Roche Holding AG
19.1 Business Overview
19.2 Initiatives/Strategies
19.2.1 Point 1
19.2.2 Point 2
19.3 Financial Insight

20. Cytokinetics, Inc.
20.1 Business Overview
20.2 Initiatives/Strategies
20.2.1 Point 1
20.2.2 Point 2
20.3 Financial Insight

List of Figures:

Figure 4‑1: Global – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 4‑2: Global – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 4‑3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 5‑1: Global – Current & Forecast for Spinal Muscular Atrophy Market Share (Percent), 2017 – 2026
Figure 5‑2: Global – Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 – 2026
Figure 5‑3: Global – Current & Forecast for Spinal Muscular Atrophy Treated Patients Share (Percent), 2017 – 2026
Figure 6‑1: United States – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 6‑2: United States – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 6‑3: United States – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 7‑1: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 7‑2: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 7‑3: United Kingdom – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 8‑1: Germany – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 8‑2: Germany – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 8‑3: Germany – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 9‑1: Italy – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 9‑2: Italy – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 9‑3: Italy – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 10‑1: France – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 10‑2: France – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 10‑3: France – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 11‑1: Spain – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 11‑2: Spain – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 11‑3: Spain – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 12‑1: Japan – Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 – 2026
Figure 12‑2: Japan – Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 – 2026
Figure 12‑3: Japan – Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 – 2026
Figure 13‑1: Global – Current & Forecast for Spinraza Sales (Million US$), 2017 – 2026
Figure 13‑2: Global – Current & Forecast for AVXS-101 Sales (Million US$), 2017 – 2026
Figure 13‑3: Global – Current & Forecast for CK212710 Sales (Million US$), 2022 – 2026
Figure 13‑4: Global – Current & Forecast for RG7916 Sales (Million US$), 2024 – 2026
Figure 13‑5: Global – Current & Forecast for LMI070 Sales (Million US$), 2021 – 2026
Figure 14‑1: Spinal Muscular Atrophy Drugs Development Pipeline, September 2018
Figure 17‑1: Biogen – Global Sales (Million US$), 2013 – 2017
Figure 17‑2: Biogen – Forecast for Global Sales (Million US$), 2018 – 2026
Figure 18‑1: Novartis – Global Sales (Million US$), 2013 – 2017
Figure 18‑2: Novartis – Forecast for Global Sales (Million US$), 2018 – 2026
Figure 19‑1: Roche – Global Sales (Million US$), 2013 – 2017
Figure 19‑2: Roche – Forecast for Global Sales (Million US$), 2018 – 2026
Figure 20‑1: Cytokinetics – Global Sales (Thousand US$), 2013 – 2017
Figure 20‑2: Cytokinetics – Forecast for Global Sales (Million US$), 2018 – 2026

List of Tables:

Table 14-1: Global – Spinal Muscular Atrophy Clinical Study Status, 2018

  • 2023-2031 Report on Global Rosacea Treatment Market by Player, Region, Type, Application and Sales Channel
    Published: 27-Mar-2023        Price: US 2500 Onwards        Pages: 104
    This report studies the Rosacea Treatment market, covering market size for segment by type (Topical, Oral, etc.), by application (Hospital Pharmacy, Retail Pharmacy, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Nestle Skin Health, Teva, Mylan, Bayer, Sun Pharma, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Rosacea Treatment from......
  • 2023-2031 Report on Global Precision Psychiatry Market by Player, Region, Type, Application and Sales Channel
    Published: 27-Mar-2023        Price: US 2500 Onwards        Pages: 100
    This report studies the Precision Psychiatry market, covering market size for segment by type (Sequencing (NGS and Sanger Sequencing) Technology, Polymerase Chain Reaction (RT-PCR and dPCR) Technology, etc.), by application (Hospitals, IDNs, etc.), by sales channel (Direct Channel, Distribution Channel), by player (llumina, Roche, Bio-Rad Laboratories, QIAGEN, Quest Diagnostics, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This......
  • 2023-2031 Report on Global Research Antibodies Market by Player, Region, Type, Application and Sales Channel
    Published: 27-Mar-2023        Price: US 2500 Onwards        Pages: 122
    This report studies the Research Antibodies market, covering market size for segment by type (Monoclonal Antibodies, Polyclonal Antibodies, etc.), by application (Pharmaceutical & Biotechnological Companies, Academic & Research Institutes, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Abcam, Affinity Biologicals, Agilent Technologies, BD, Bethyl Laboratories, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). ......
  • 2023-2031 Report on Global Primary Antibody Market by Player, Region, Type, Application and Sales Channel
    Published: 27-Mar-2023        Price: US 2500 Onwards        Pages: 122
    This report studies the Primary Antibody market, covering market size for segment by type (Monoclonal Antibodies, Polyclonal Antibodies, etc.), by application (Pharmaceutical & Biotechnological Companies, Academic & Research Institutes, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Abcam, Affinity Biologicals, Agilent Technologies, BD, Bethyl Laboratories, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). ......
  • 2023-2031 Report on Global Oral Insulin Market by Player, Region, Type, Application and Sales Channel
    Published: 27-Mar-2023        Price: US 2500 Onwards        Pages: 84
    This report studies the Oral Insulin market, covering market size for segment by type (Type 1 Diabete Insulin, Type 2 Diabete Insulin, etc.), by application (Female, Male, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Novo Nordisk, Oramed Pharmaceuticals, vTv Therapeutics, Diabetology, Generex Biotechnology, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analys......
  • 2023-2031 Report on Global Rosacea Therapeutics Market by Player, Region, Type, Application and Sales Channel
    Published: 27-Mar-2023        Price: US 2500 Onwards        Pages: 102
    This report studies the Rosacea Therapeutics market, covering market size for segment by type (Topical, Oral, etc.), by application (Hospital Pharmacy, Retail Pharmacy, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Nestle Skin Health, Teva, Mylan, Bayer, Sun Pharma, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Rosacea Therapeutic......
  • Global Keyhole Limpet Hemocyanin (Klh) Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 23-Mar-2023        Price: US 3260 Onwards        Pages: 118
    The Keyhole Limpet Hemocyanin (Klh) market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Keyhole Limpet Hemocyanin (Klh) industry, and breaks down according to the type, application, and consumption area of Keyhole Limpet Hemocyanin (Klh). The report also introduces players in the industry from the perspective of the industry ch......
  • Global Recombinant Protein Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 23-Mar-2023        Price: US 3260 Onwards        Pages: 127
    The Recombinant Protein market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Recombinant Protein industry, and breaks down according to the type, application, and consumption area of Recombinant Protein. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describe......
  • Global Chitosan Gel Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 23-Mar-2023        Price: US 3260 Onwards        Pages: 108
    The Chitosan Gel market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Chitosan Gel industry, and breaks down according to the type, application, and consumption area of Chitosan Gel. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading compani......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs